Skip to Content

How is Vantrela ER formulated to be abuse deterrent?

Medically reviewed by Last updated on Jan 29, 2020.

Official Answer


Vantrela ER (hydrocodone bitartrate) extended-release tablets are formulated with Teva Pharmaceutical's abuse-deterrent technology that results in properties that are expected to reduce, but not totally prevent, oral, intranasal and intravenous abuse of the drug when the tablets are manipulated.

Teva's proprietary abuse-deterrent technology is based on a multi-layer gel-forming polymer coating that regulates drug release.

Related Medical Questions

Drug Information

Related Support Groups